Methods of producing high specific activity Sn-117m with commercial cyclotrons
- 191 Downloads
- 9 Citations
Abstract
Sn-117m is a theragnostic isotope of increasing interest. It has ideal imaging and therapeutic properties for many applications. Production of high specific activity Sn-117m can only be achieved with accelerators and the Sb(p,x) and Cd-116(α,3n) reactions provide the highest yields for this isotope. This paper describes the production and a new purification method for obtaining commercial quantities of Sn-117m via the Cd-116(α,3n) reaction. The purified Sn-117m has subsequently been chelated with an aminobenzyl derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and then conjugated with annexin V-128 to produce an agent for the diagnosis and treatment of vulnerable plaque.
Keywords
Sn-117m Theragnostic Accelerator produced isotope High specific activityNotes
Acknowledgments
The authors acknowledge the pioneering work of Dr. Claude Meares and his group at the University of California, Davis in forming [Sn-117m]-DOTA linked molecules. The authors would also like to thank the staff at the University of Washington MC50 Cyclotron for providing irradiation services in the production of Sn-117m. This work was supported in part by the US Department of Energy (Office of Science/NP Office of Nuclear Physics, Isotope Development and Production for Research and Applications) SBIR Program and the NNSA NA-24 GIPP Program, under Contract # DE-AC02-98CH10886 at Brookhaven National Laboratory. The work described here is the subject of US Patents 8,257,681, 8,283,167, 8,632,748, 8,097,064, 8,449,816, 8,705,681, 8,290,110, including continuations and international counterparts.
References
- 1.Krishnamurthy GT et al (1997) J Nucl Med 38:230–237Google Scholar
- 2.Bishayee A et al (2000) J Nucl Med 41:2043–2050Google Scholar
- 3.Swailem FM et al (1998) Nucl Med Biol 25:279–287CrossRefGoogle Scholar
- 4.Qaim SM, Dohler H (1984) Int J Appl Radiat Isot 35(7):645–650CrossRefGoogle Scholar
- 5.Fukushima S et al (1963) Bull Chem Soc Jpn 36(10):1225–1228CrossRefGoogle Scholar
- 6.Montgomery DM, Porile NT (1969) Nucl Phys A 130:65–76CrossRefGoogle Scholar
- 7.Adam Rebeles R et al (2008) Nucl Instrum Methods B266:4731–4737CrossRefGoogle Scholar
- 8.Maslov OD et al (2011) Appl Radiat Isot 69:965–968CrossRefGoogle Scholar
- 9.Ghosh K et al (2013) J Radioanal Nucl Chem 295:865–870CrossRefGoogle Scholar
- 10.Nortier M, Stevenson NR, Gelbart W (1995) Nucl Instrum Meth A355:236–241CrossRefGoogle Scholar
- 11.Dorman E, Emery R (2014) Isotope production and clinical research at the University of Washington clinical cyclotron, 8th international conference on isotopes, ChicagoGoogle Scholar
- 12.Srivastava SC (2012) Semin Nucl Med 42:151–163CrossRefGoogle Scholar
- 13.Srivastava SC (2006) In: Mazzi U (ed) Technetium, rhenium, and other metals in chemistry and nuclear medicine. SG Editorial, Padova, pp 553–568Google Scholar
- 14.Mausner LF, Mirzadeh S, Srivastava SC (1992) Appl Radiat Isot 43:1117–1122CrossRefGoogle Scholar
- 15.Srivastava SC et al (1998) Clin Cancer Res 4:61–68Google Scholar
- 16.Ermolaev SV et al (2009) J Radioanal Nucl Chem 280:319–324CrossRefGoogle Scholar
- 17.Mausner LF et al (1998) Appl Radiat Isot 49:285–294CrossRefGoogle Scholar
- 18.Stevenson NR, Horn IM (2012) US Patent 8,257,681Google Scholar
- 19.Simon J et al (2013) Sn-117m labeled annexin for vulnerable plaque, American Chemical Society Annual meeting, New Orleans, USAGoogle Scholar
- 20.Stevenson NR (2013) Production and applications of high specific activity Sn-117m labeled compounds, Radiometals 2013, Sonoma Valley, CA, USAGoogle Scholar
- 21.Simon J et al (2014) Preparation and evaluation of Sn-117m annexin for vulnerable plaque, proceedings 8th international conference on isotopes, Chicago, USAGoogle Scholar
- 22.Zheng M (2007) Synthesis and medical application of bifunctional metal chelates, Ph.D. Dissertation, UC Davis, USAGoogle Scholar
- 23.Stevenson NR et al (2013) Production and applications of very high specific activity Sn-117m, American Chemical Society Annual meeting, New Orleans, USAGoogle Scholar
- 24.Gonzales GR (2012) Tin-117m-DOTA-Annexin for imaging and treating vulnerable plaque, international conference on radiopharmaceutical therapy (ICRT/WARMTH), FinlandGoogle Scholar
- 25.Jaimovich R et al (2013) Sn117m-DOTA-annexin as a novel vulnerable plaque tracer: first time in humans trial, IAEA International Conference on Integrated Medical Imaging in cardiovascular disease, Vienna, AustriaGoogle Scholar
- 26.Srivastava SC, Narula J, Strauss HW, Gonzales G (2013) Simultaneous imaging and treatment of vulnerable plaques with tin-117m-DOTA-Annexin, WIPR 2013: latest progress in the field of radio immunotherapy, Nantes, FranceGoogle Scholar
- 27.Stevenson NR et al (2013) Manufacturing and integrated medical imaging of high specific activity [Sn-117m]-annexin in cardiovascular disease, IAEA International Conference on Integrated Medical imaging in cardiovascular disease, Vienna, AustriaGoogle Scholar
- 28.Strauss HW et al (2013) Targeting of vulnerable plaque using [tin-117m]-DOTA-annexin. Vancouver, CanadaGoogle Scholar
- 29.Srivastava SC et al (2013) Theragnostic potential of Sn-117m for the molecular targeting and therapy of vulnerable plaque, Annual meeting of the society of nuclear medicine and molecular imaging, Vancouver, CanadaGoogle Scholar